The efficacy seen with ripretinib (Qinlock) in patients with KIT-mutated melanoma was higher than has been previously reported, according to Filip Janku, MD, PhD. Furthermore, the switch-control tyrosine kinase inhibitor (TKI) has elicited durable responses, even in patients who were heavily pretreated, making the drug a powerful tool for this patient population.
Archive | Clinical Trials
Ripretinib Demonstrates Impressive Efficacy, Durability in Heavily Pretreated KIT-Mutated Melanoma
Posted in Melanoma News, Health Professionals, Clinical Trials
Darovasertib/Crizotinib Shows Early Efficacy in Metastatic Uveal Melanoma
Darovasertib and crizotinib demonstrated promising efficacy and tolerable safety in patients with metastatic uveal melanoma, according to preliminary results of a phase 1/2 trial announced in a press release from IDEAYA Biosciences.
Posted in Melanoma News, Health Professionals, Clinical Trials
Neoadjuvant T-VEC Improves Survival in Resectable Melanoma
Neoadjuvant talimogene laherparepvec (T-VEC) followed by surgery significantly improved survival, when compared with surgery alone, in patients with advanced…
Posted in Melanoma News, Health Professionals, Clinical Trials
Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer
Nouscom said on Tuesday it has dosed the first patient in a Phase Ib trial of its neoantigen cancer vaccine, NOUS-PEV, plus pembrolizumab (Merck’s Keytruda) in patients with advanced melanoma and non-small cell lung cancer.
Posted in Melanoma News, Health Professionals, Clinical Trials
 |
 |
 |
 |
